Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
biotechs: Archive
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.
GILDNegative Net Change ONCYPositive Net Change FATEPositive Net Change OMGAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
by Zacks Equity Research
Investors are likely to focus on Opdivo's demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) posts Q1 results.
BMYPositive Net Change ONCYPositive Net Change FATEPositive Net Change OMGAPositive Net Change
biotechnology biotechs earnings pharmaceuticals
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports first-quarter results.
SRPTNegative Net Change ABBVNegative Net Change CTMXNegative Net Change LABPPositive Net Change
biotechs medical pharmaceuticals
Here's Why You Should Add Immunovant (IMVT) to Your Portfolio
by Zacks Equity Research
Immunovant's (IMVT) late-stage studies evaluating its lead candidate, batoclimab, for various autoimmune indications are progressing well. Several data readouts are expected in 2024 and 2025.
ADMAPositive Net Change FGENPositive Net Change IMVTNegative Net Change ANVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug
by Zacks Equity Research
Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024.
VRTXPositive Net Change ADMAPositive Net Change FGENPositive Net Change ANVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Viking (VKTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports first-quarter earnings results.
SRPTNegative Net Change VKTXPositive Net Change CTMXNegative Net Change ARGXNegative Net Change
biotechs medical pharmaceuticals
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
by Zacks Equity Research
Bio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its investigational candidate, BP1002, to treat acute myeloid leukemia patients.
BPTHPositive Net Change ADMAPositive Net Change FGENPositive Net Change ANVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
What's in Store for Biogen (BIIB) This Earnings Season?
by Zacks Equity Research
Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been moderate.
BIIBPositive Net Change NVAXNo Net Change FATEPositive Net Change SAGENegative Net Change
biotechs
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
by Zacks Equity Research
Regeneron (REGN) and Sage Therapeutics (SAGE) are in focus on regulatory and pipeline updates.
REGNPositive Net Change GSKPositive Net Change ITCINegative Net Change SAGENegative Net Change NMRAPositive Net Change
biotechnology biotechs pharmaceuticals
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
by Zacks Equity Research
DiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke.
ADMAPositive Net Change FGENPositive Net Change DMACNegative Net Change ANVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up
by Zacks Equity Research
Vanda's (VNDA) board of directors unanimously rejects takeover proposals from Future Pak to acquire all outstanding shares of Vanda. Shares rise on the news.
LGNDPositive Net Change VNDANegative Net Change ANIPPositive Net Change ADMAPositive Net Change
biotechs
2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why
by Zacks Equity Research
The FDA's recent nod to 2seventy bio's (TSVT) Abecma in earlier lines of treatment for relapsed/refractory multiple myeloma is a positive. Also, the R&D asset divestiture to Regeneron is saving costs.
REGNPositive Net Change BMYPositive Net Change ADMAPositive Net Change TSVTNegative Net Change
biotechs
Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals
by Zacks Equity Research
Intra-Cellular (ITCI) jumps 23% after achieving key goals in the late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
ITCINegative Net Change ADMAPositive Net Change FGENPositive Net Change ANVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
bluebird (BLUE) Underperforms Industry YTD Amid Challenges
by Zacks Equity Research
bluebird (BLUE) plunges 25% year to date as it struggles to fuel the growth of its complex and expensive gene therapies.
VRTXPositive Net Change BLUEPositive Net Change ADMAPositive Net Change CRSPPositive Net Change
biotechnology biotechs pharmaceuticals
Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why
by Zacks Equity Research
Aptevo (APVO) plunges after it issues secondary shares, which are not only issued at a significant discount but also substantially dilute the existing shareholder base.
LGNDPositive Net Change ANIPPositive Net Change ADMAPositive Net Change APVONegative Net Change
biotechs medical
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
by Zacks Equity Research
Ultragenyx (RARE) reports positive interim data from the phase I/II study of GTX-102 for Angelman syndrome. However, the stock declines due to safety concerns.
RARENegative Net Change ADMAPositive Net Change FGENPositive Net Change ANVSPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug
by Zacks Equity Research
The FDA places a clinical hold on Neumora's (NMRA) phase I study evaluating NMRA-266 for some types of neuropsychiatric disorders. Shares of the company fall on the news.
LGNDPositive Net Change ANIPPositive Net Change ADMAPositive Net Change NMRAPositive Net Change
biotechs
Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
by Zacks Equity Research
Xilio (XLO) rallies 79.8% in a month on an exclusive global licensing agreement with Gilead Sciences to develop XTX301 for advanced solid tumors.
GILDNegative Net Change FGENPositive Net Change ANVSPositive Net Change XLOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Adaptimmune (ADAP) Down on End of Collaboration With Roche
by Zacks Equity Research
Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.
GSKPositive Net Change RHHBYPositive Net Change PSTXNo Net Change ADAPNo Net Change
biotechnology biotechs pharmaceuticals
Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors
by Zacks Equity Research
Janux (JANX) stock surges after some reports claim that the company is exploring opportunities for a potential sale following buyout offers from big pharma companies.
LGNDPositive Net Change ANIPPositive Net Change ADMAPositive Net Change JANXNegative Net Change
biotechs
Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
by Zacks Equity Research
Roche's (RHHBY) Columvi, in combination with GemOx, achieves the primary endpoint of overall survival in a late-stage lymphoma study.
RHHBYPositive Net Change BMYPositive Net Change ALXOPositive Net Change NRIXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron (REGN) Accused of Fraudulent Practices Related to Eylea
by Zacks Equity Research
The U.S. Department of Justice files a complaint against Regeneron (REGN), alleging fraudulent drug pricing practices related to its lead drug, Eylea.
REGNPositive Net Change RHHBYPositive Net Change BAYRYPositive Net Change ADMAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex
by Zacks Equity Research
Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024.
VRTXPositive Net Change CRSPPositive Net Change ALPNPositive Net Change VERANegative Net Change
biotechs gene-therapy medical pharmaceuticals
RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up
by Zacks Equity Research
RallyBio (RLYB) gains 83% after announcing a collaboration deal with J&J to develop novel therapies to reduce the risk of FNAIT in pregnant women, along with funding of $6.6 million from the latter.
JNJPositive Net Change FGENPositive Net Change ANVSPositive Net Change RLYBPositive Net Change
biotechnology biotechs medical pharmaceuticals
Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag
by Zacks Equity Research
Candel (CADL) rallies 43% as the FDA grants the orphan drug designation to its lead candidate, CAN-2409, for treating non-metastatic pancreatic cancer.
ADMAPositive Net Change FGENPositive Net Change ANVSPositive Net Change CADLNegative Net Change
biotechnology biotechs medical pharmaceuticals